Allergy Therapeutics (AGY) - Total Assets

Latest as of December 2025: GBX71.00 Million GBX ≈ $8.64K USD

Based on the latest financial reports, Allergy Therapeutics (AGY) holds total assets worth GBX71.00 Million GBX (≈ $8.64K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Allergy Therapeutics - Total Assets Trend (2002–2025)

This chart illustrates how Allergy Therapeutics's total assets have evolved over time, based on quarterly financial data. Also see AGY stock market capitalisation for the company's overall valuation and market capitalisation.

Allergy Therapeutics - Asset Composition Analysis

Current Asset Composition (June 2025)

Allergy Therapeutics's total assets of GBX71.00 Million consist of 51.3% current assets and 48.7% non-current assets. Review total liabilities of Allergy Therapeutics to assess the company's total debt and financial obligations.

Asset Category	Amount (GBX)	% of Total Assets
Cash & Equivalents	GBX0.00	18.9%
Accounts Receivable	GBX7.97 Million	11.8%
Inventory	GBX13.91 Million	20.6%
Property, Plant & Equipment	GBX0.00	0.0%
Intangible Assets	GBX931.00K	1.4%
Goodwill	GBX3.33 Million	4.9%

Asset Composition Trend (2002–2025)

This chart illustrates how Allergy Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AGY share price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Allergy Therapeutics's current assets represent 51.3% of total assets in 2025, an increase from 37.0% in 2002.
Cash Position: Cash and equivalents constituted 18.9% of total assets in 2025, up from 0.6% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 49.0% in 2002.
Asset Diversification: The largest asset category is inventory at 20.6% of total assets.

Allergy Therapeutics Competitors by Total Assets

Key competitors of Allergy Therapeutics based on total assets are shown below.

Company	Country	Total Assets
Torrent Pharmaceuticals Limited NSE:TORNTPHARM	India	Rs443.12 Billion
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Sweden	Skr81.26 Billion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Germany	€1.60 Trillion
Beijing Tongrentang Co Ltd SHG:600085	China	CN¥29.95 Billion
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	China	CN¥19.57 Billion
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	China	CN¥12.75 Billion
Harbin Pharmaceutical Group Co Ltd SHG:600664	China	CN¥14.08 Billion
Kangmei Pharmaceutical Co Ltd SHG:600518	China	CN¥13.68 Billion

Allergy Therapeutics - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.13	1.60	4.23
Quick Ratio	0.70	1.15	3.61
Cash Ratio	0.00	0.00	0.00
Working Capital	GBX4.22 Million	GBX15.73 Million	GBX52.80 Million

Allergy Therapeutics - Advanced Valuation Insights

This section examines the relationship between Allergy Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	70.79
Latest Market Cap to Assets Ratio	0.05
Asset Growth Rate (YoY)	4.2%
Total Assets	GBX67.54 Million
Market Capitalization	$3.66 Million USD

Valuation Analysis

Below Book Valuation: The market values Allergy Therapeutics's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Allergy Therapeutics's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Allergy Therapeutics (2002–2025)

The table below shows the annual total assets of Allergy Therapeutics from 2002 to 2025.

Year	Total Assets	Change
2025-06-30	GBX67.54 Million ≈ $8.22K	+4.19%
2024-06-30	GBX64.83 Million ≈ $7.89K	-2.91%
2023-06-30	GBX66.77 Million ≈ $8.12K	-8.47%
2022-06-30	GBX72.95 Million ≈ $8.88K	-17.19%
2021-06-30	GBX88.09 Million ≈ $10.72K	+2.16%
2020-06-30	GBX86.22 Million ≈ $10.49K	+25.88%
2019-06-30	GBX68.50 Million ≈ $8.33K	+34.27%
2018-06-30	GBX51.02 Million ≈ $6.21K	-10.78%
2017-06-30	GBX57.18 Million ≈ $6.96K	+0.89%
2016-06-30	GBX56.68 Million ≈ $6.90K	+11.80%
2015-06-30	GBX50.70 Million ≈ $6.17K	+78.53%
2014-06-30	GBX28.40 Million ≈ $3.46K	-1.95%
2013-06-30	GBX28.96 Million ≈ $3.52K	+4.36%
2012-06-30	GBX27.75 Million ≈ $3.38K	-9.36%
2011-06-30	GBX30.62 Million ≈ $3.73K	+5.17%
2010-06-30	GBX29.11 Million ≈ $3.54K	+31.88%
2009-06-30	GBX22.08 Million ≈ $2.69K	-4.77%
2008-06-30	GBX23.18 Million ≈ $2.82K	-3.38%
2007-06-30	GBX23.99 Million ≈ $2.92K	-36.66%
2006-06-30	GBX37.88 Million ≈ $4.61K	+42.09%
2005-06-30	GBX26.66 Million ≈ $3.24K	+137.32%
2004-06-30	GBX11.23 Million ≈ $1.37K	+0.76%
2003-06-30	GBX11.15 Million ≈ $1.36K	+15.22%
2002-06-30	GBX9.68 Million ≈ $1.18K	--

About Allergy Therapeutics

LSE:AGY UK Drug Manufacturers - Specialty & Generic

Market Cap

$3.66 Million

GBX30.08 Billion GBX

Market Cap Rank

#29251 Global

#547 in UK

Share Price

GBX4.75

Change (1 day)

+0.00%

52-Week Range

GBX4.75 - GBX12.10

All Time High

GBX38.50